Kerrie Brady is a successful serial biotechnology entrepreneur and strategic business leader with over 30 years of international experience across a variety of therapeutic areas. Prior to joining OcuTerra as CEO and President, Kerrie co-founded Centrexion Therapeutics and served as its CBO and Executive VP Strategy. She played a key role in growing the initial team from two people to a high-performing 25-person team with five clinical programs. She was instrumental in raising over $150 million in investments and led the $998 million out-licensing deal to Lilly.